Italy Galenici Personalizzati (Personalized Compounding Pharmaceuticals) Market Size, Trends & Growth Opportunity By Preparation Type, By Dosage Form, By Therapeutic Application, By Pharmacy Type, By Region and Forecast Till 2030

Report ID : AMR1006103 | Industries : Healthcare | Published On :September 2026 | Page Count : 226

Request Sample
Ask for Customization

The Italy Galenici Personalizzati market covers personalized magistral and officinal compounding preparations dispensed through galenic and compounding pharmacies across Italy.

Galenici Personalizzati, literally personalized galenicals, is the Italian term for personalized compounding pharmaceuticals, and this report describes the category strictly as a market segment.

A magistral preparation is a medicine compounded in a pharmacy on the basis of an individual physician's prescription for a specific patient, and an officinal preparation is compounded to a recognised pharmacopoeia formula rather than an individual prescription; this report makes no claim about clinical efficacy, therapeutic benefit, symptom relief, safety outcome or health outcome for any preparation, therapeutic application or company described on these pages.

Nine segmentation dimensions appear in this report, and the first two describe the preparation type supplied and the manufacturing complexity it requires.

Preparation type spans six categories, from magistral and officinal preparations through sterile and non-sterile compounded preparations to personalized nutraceutical formulations and veterinary galenic preparations.

Manufacturing complexity covers four categories, from simple compounding through medium complexity and advanced personalized formulations to sterile high-control preparations, and regulatory classification spans a further four categories including Agenzia Italiana del Farmaco (AIFA)-compliant preparations, European Pharmacopoeia-based preparations, controlled substance preparations and specialized therapeutic preparations.

The most useful commercial observation about this market is that manufacturing complexity, not preparation type category alone, is the specification decision that determines which pharmacy can actually compound a given preparation.

Whether a preparation requires simple, medium, advanced personalized or sterile high-control compounding determines which of the six preparation type categories and which regulatory classification are even viable before a specific pharmacy relationship is confirmed.

Dosage form is the widest dimension in this report at fifteen categories, spanning capsules, powders, oral liquids, syrups, suspensions, creams, ointments, gels, lotions, suppositories, vaginal preparations, ophthalmic preparations, injectable preparations, nasal formulations and transdermal preparations.

Therapeutic application covers thirteen categories including dermatology, hormone replacement therapy, pain management, pediatrics, geriatrics, rare diseases, oncology supportive care, endocrinology, gastroenterology, neurology, women's health, men's health and veterinary medicine, and patient category spans six further categories from adult and pediatric patients through geriatric, chronic disease, special needs and rare disease patients.

Prescription model spans four categories, pharmacy type covers a further four categories, and business model completes the segmentation across four categories including direct patient service, physician referral, hospital partnership and business-to-business (B2B) pharmacy supply models.

This report covers personalized magistral and officinal compounding preparations, including sterile and non-sterile compounded formulations, personalized nutraceutical formulations and veterinary galenic preparations, dispensed through Italian galenic and compounding pharmacies.

It excludes commercially manufactured, mass-produced pharmaceutical products and non-personalized over-the-counter medicines outside this report's compounding scope.

Buyer intelligence in the full report maps independent physicians, specialist clinics, hospitals, healthcare networks and veterinary clinics across Northern, Central and Southern Italy and Sicily and the islands, including a dedicated strategic relevance assessment for Sella Farmaceutici.

Competitive benchmarking compares pharmacies across estimated market presence, product breadth, therapeutic coverage, geographic reach and four further metrics without disclosing proprietary competitive positioning data.

Market Size and Growth Forecast (2026 to 2030)

The Italy Galenici Personalizzati market is estimated at approximately USD 380 Million in 2025 and is projected to reach approximately USD 495 Million by 2030, expanding at a compound annual growth rate of roughly 5.4 percent.

The estimate covers personalized magistral and officinal compounding preparations dispensed through Italian galenic and compounding pharmacies, and excludes commercially manufactured, mass-produced pharmaceutical products.

Magistral preparations account for the largest preparation type category by revenue, while personalized nutraceutical formulations form a fast-growing preparation type category.

Oral dosage forms, capsules, powders, oral liquids, syrups and suspensions together, account for the largest dosage form category by volume, and injectable preparations form a fast-growing dosage form category tied to rising biologic and hormone therapy demand.

Pain management accounts for the largest therapeutic application category by revenue, and hormone replacement therapy forms a fast-growing therapeutic application category.

Adult patients account for the largest patient category, and geriatric patients form a fast-growing patient category tied to Italy's ageing population.

Physician-prescribed magistral preparations account for the largest prescription model category, and hospital-originated prescriptions form a fast-growing prescription model category tied to commercial product shortage activity.

Independent galenic pharmacies account for the largest pharmacy type category, and integrated pharmacy chains with compounding capability form a fast-growing pharmacy type category.

Simple compounding accounts for the largest manufacturing complexity category by volume, and sterile high-control preparations form a fast-growing manufacturing complexity category tied to hospital and specialist demand.

Lombardy accounts for the largest regional concentration in this report, and Campania forms a fast-growing region tied to expanding Southern Italy healthcare infrastructure.

The forecast assumes Italian healthcare, physician referral and hospital tender activity continues broadly on recent trends, and a material shift in AIFA regulatory policy or reimbursement practice would move the trajectory.

MetricValue
Market Size (2025)Approximately USD 380 Million
Forecast Size (2030)Approximately USD 495 Million
CAGR (2025-2030)Approximately 5.4%
Base Year2025
Forecast Period2026-2030 (5-year)
Scope NotePersonalized magistral and officinal compounding preparations dispensed through Italian galenic and compounding pharmacies only; excludes commercially manufactured, mass-produced pharmaceutical products
Largest Preparation CategoryMagistral preparations
Fastest-Growing Preparation CategoryPersonalized nutraceutical formulations
Largest Therapeutic ApplicationPain management
Fastest-Growing Therapeutic ApplicationHormone replacement therapy
Largest Regional ConcentrationLombardy
Fastest-Growing RegionCampania

Market Drivers

Rising patient-specific dosage customization needs, including allergy-free and non-standard-strength formulations, that route physician referrals toward compounding pharmacies.

Commercial product shortages of standard-dose medicines, prompting physicians and hospital pharmacists to source magistral preparations as a qualified fallback.

Growing adoption of personalized and precision-dosing approaches among Italian prescribers, widening demand beyond a small set of legacy therapeutic categories.

Expansion of digital prescription infrastructure, streamlining referral and fulfillment between physicians and galenic pharmacies.

Growth in rare disease and pediatric prescribing where a commercially manufactured dose form does not exist, requiring magistral or officinal compounding.

Rising demand for hormone replacement therapy formulations tailored to individual dosing requirements, reflecting broader biologic and hormone therapy growth identified across the wider Italian pharmaceutical sector.

Expansion of veterinary galenic preparation demand, as veterinary clinics increasingly reference the same personalized dosing logic used in human prescribing.

Growth in hospital tender procurement for sterile compounded preparations, tied to hospital pharmacy departments consolidating specialist compounding relationships.

Increasing prescriber engagement models and physician network development activity among pharmacies seeking to broaden referral relationships beyond a single specialist clinic.

Market Restraints

Regulatory and compliance requirements under AIFA and European Pharmacopoeia standards, which govern which preparations a pharmacy may compound and lengthen new-supplier qualification timelines.

Dependence on physician and hospital pharmacist referral relationships, which take time to establish and sit outside any single compounding pharmacy's direct control.

Raw material cost dynamics for active pharmaceutical ingredients and excipients, which bear directly on compounding cost and pricing.

Competition between national specialists and regional compounding pharmacies, fragmenting therapeutic specialization and geographic coverage.

Long qualification periods before a hospital pharmacy department approves a new compounding pharmacy for a tender or framework agreement.

Fragmented demand across smaller neighbourhood pharmacies, which raises the cost of serving that segment commercially relative to larger multi-city operators.

Skilled compounding personnel availability constraints, which can affect both new formulation capability and ongoing prescriber technical support capacity.

Controlled substance preparation handling requirements, which require pharmacies to maintain additional documentation and security systems beyond standard compounding.

Extended technical support expectations from hospital and specialist clinic buyers, which add ongoing commercial obligations beyond the initial prescription fulfillment.

PROCUREMENT INSIGHT

Hospital pharmacy departments increasingly qualify a compounding pharmacy well before a specific tender is issued, meaning a long qualification and compliance documentation period functions as a genuine barrier to entry rather than a one-time onboarding cost.

 

Market Opportunities

Underserved therapeutic categories identified in the report competitive mapping.

Considerable untapped regional opportunity relative to the concentration of established compounding pharmacies in Northern Italy.

Rare disease opportunities identified in the report competitive mapping, where commercial dose forms remain unavailable.

Veterinary compounding gaps identified in the report competitive mapping.

Personalized nutraceutical opportunities identified in the report competitive mapping.

Specialty hormone therapy opportunities identified in the report competitive mapping.

Growth in digital prescription tools, which several pharmacies are using to differentiate their prescriber engagement and referral relationships.

Expansion of hospital partnership models, tied to hospital pharmacy departments consolidating specialist compounding relationships with fewer, more capable suppliers.

MARKET SHIFT

Rare disease and veterinary compounding gaps are underserved by pharmacies with deep specialty formulation expertise even as personalized nutraceutical formulations form this market's fastest-growing preparation type category, leaving a specification-support gap that digital prescription tools are only beginning to close.

 

Preparation Types and Manufacturing Complexity

Physicians and hospital pharmacists evaluating preparation types and manufacturing complexity increasingly weigh regulatory classification alongside compounding complexity when confirming a pharmacy relationship, since magistral, officinal, sterile compounded, non-sterile compounded, personalized nutraceutical and veterinary galenic preparations each require a different combination of simple, medium, advanced personalized or sterile high-control compounding capability.

Dosage Forms and Administration Routes

Capsules, powders, oral liquids, syrups, suspensions, creams, ointments, gels, lotions, suppositories, vaginal preparations, ophthalmic preparations, injectable preparations, nasal formulations and transdermal preparations are compounded across a range of administration routes, and the resulting dosage form and administration route pairing often determines which pharmacies a prescriber can shortlist for a given preparation.

Therapeutic Applications and Patient Categories

Dermatology, hormone replacement therapy, pain management, pediatrics, geriatrics, rare diseases, oncology supportive care, endocrinology, gastroenterology, neurology, women's health, men's health and veterinary medicine serve adult, pediatric, geriatric, chronic disease, special needs and rare disease patients, and this spread of therapeutic applications and patient categories shapes which preparation format a given case ultimately requires.

Prescription Models and Pharmacy Types

Physician-prescribed magistral, specialist-initiated, hospital-originated and veterinary prescriptions are fulfilled through independent galenic pharmacies, specialized compounding pharmacies, hospital pharmacies and integrated pharmacy chains under direct patient service, physician referral, hospital partnership and B2B pharmacy supply business models, a mix of prescription models and pharmacy types that varies considerably by therapeutic application.

Galenici Personalizzati Market, By Region

This report covers Italy, reflecting where the country's compounding pharmacy activity is concentrated across eight named regions.

Lombardy accounts for the largest regional concentration in this report, covered through Milan, Brescia and Bergamo, anchored by the Lombardy Healthcare Cluster and a dense concentration of hospital and specialist referral relationships.

Veneto and Emilia-Romagna represent established regional concentrations, covered through Padua, Venice and Verona, and Bologna, Parma and Modena respectively, anchored by the Veneto Healthcare Cluster and the Emilia-Romagna Medical Innovation Corridor.

Lazio, covered through Rome, is anchored by the Rome Healthcare Network, and Piedmont and Tuscany, covered through Turin and Florence respectively, round out the Central and Northern Italy buyer mapping zones.

Campania and Sicily, covered through Naples, and Palermo and Catania respectively, represent the Southern Italy and Sicily and Islands buyer mapping zones, with Campania forming a fast-growing regional concentration tied to expanding Southern Italy healthcare infrastructure.

Regional sizing, growth rates and province or city-level breakdowns are reserved for the full report rather than presented on this page.

REGIONAL OPPORTUNITY

Southern Italy and Sicily carry a materially thinner concentration of established compounding pharmacies than Lombardy, Veneto and Emilia-Romagna, a regional imbalance the report's own competitive mapping identifies as considerable untapped regional opportunity rather than an already-served market.

 

Leading Companies

Sella Farmaceutici, Farmacia Sant'Antonio, Farmacia Legnani, Farmacia Serra, Farmacia Internazionale, Farmacia Del Naviglio, Farmacia San Carlo, Farmacia Vigorito, Farmacia San Giuseppe, Farmacia Mazzini, Farmacia Loreto, Farmacia Al Vigentino, Farmacia del Corso, Farmacia Centrale Firenze, Farmacia Comunale Torino, Farmacia del Leone, Farmacia Federici and Farmacia Cavour are covered in the full report. An introduction to the compounding pharmacy landscape by company type is available on the leading Galenici Personalizzati compounding pharmacies in Italy page.

Beyond This Page

The full report extends well past the segmentation summarised here and into the commercial detail that shapes how personalized compounding pharmaceutical supply is actually won in Italy.

Buyer intelligence maps the buyer ecosystem across independent physicians, specialist clinics, hospitals, healthcare networks and veterinary clinics in full, including a dedicated strategic relevance assessment for Sella Farmaceutici.

Decision-maker mapping covers vendor selection criteria, budget ownership, contract value bands and typical sales cycle length.

Competitive benchmarking compares pharmacies across product breadth, therapeutic coverage, geographic reach, laboratory capabilities and sterile preparation capability.

The market playbook covers pricing structure analysis, raw material cost dynamics, regulatory and compliance developments and digital prescription trends.

Pricing and procurement chapters cover galenic preparation pricing analysis, therapeutic category pricing comparison, procurement lifecycle assessment and total cost of ownership considerations.

Go-to-market chapters set out prescriber engagement models, physician network development, hospital partnership strategy and key Italian healthcare events and trade fairs.

Company profiles cover eighteen pharmacies across geographic footprint, personalized galenic portfolio, regulatory certifications and R&D and formulation innovation capabilities.

Frequently Asked Questions

Galenici Personalizzati, personalized compounding pharmaceuticals, covers magistral and officinal preparations compounded in pharmacy for individual patients. The Italy market is estimated at approximately USD 380 Million in 2025 and is projected to reach approximately USD 495 Million by 2030, expanding at a compound annual growth rate of roughly 5.4 percent.

A medicine compounded in a pharmacy on the basis of an individual physician's prescription for a specific patient. This report describes the category strictly as a market segment.

Lombardy accounts for the largest regional concentration, covered through Milan, Brescia and Bergamo, anchored by the Lombardy Healthcare Cluster and a dense concentration of hospital and specialist referral relationships.

Rising patient-specific dosage customization needs are the leading driver, including allergy-free and non-standard-strength formulations that route physician referrals toward compounding pharmacies.

A magistral preparation is compounded on the basis of an individual physician's prescription for a specific patient, while an officinal preparation is compounded to a recognised pharmacopoeia formula rather than an individual prescription.

Independent physicians, specialist clinics and hospitals most commonly prescribe these preparations, working within physician-prescribed magistral, specialist-initiated, hospital-originated or veterinary prescription models.

Pain management generates particularly consistent demand, alongside steady demand from dermatology, hormone replacement therapy and pediatrics.

AIFA-compliant preparations are one of four regulatory classification categories this report tracks, reflecting a preparation's alignment with Agenzia Italiana del Farmaco requirements as a market-access category rather than a description of any clinical outcome.

Fifteen dosage forms are tracked, from capsules, powders and oral liquids through creams, gels and suppositories to injectable and transdermal preparations, each paired with a specific administration route.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Galenici Personalizzati Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Rising Patient-Specific Dosage Customization Needs, Including Allergy-Free and Non-Standard-Strength Formulations, That Route Physician Referrals Toward Compounding Pharmacies.

3.3.2. Commercial Product Shortages of Standard-Dose Medicines, Prompting Physicians and Hospital Pharmacists to Source Magistral Preparations as a Qualified Fallback.

3.3.3. Growing Adoption of Personalized and Precision-Dosing Approaches Among Italian Prescribers, Widening Demand Beyond a Small Set of Legacy Therapeutic Categories.

3.3.4. Expansion of Digital Prescription Infrastructure, Streamlining Referral and Fulfillment Between Physicians and Galenic Pharmacies.

3.3.5. Growth in Rare Disease and Pediatric Prescribing Where a Commercially Manufactured Dose Form Does Not Exist, Requiring Magistral or Officinal Compounding.

3.4. Restraints

3.4.1. Regulatory and Compliance Requirements Under AIFA and European Pharmacopoeia Standards, Which Govern Which Preparations a Pharmacy May Compound and Lengthen New-Supplier Qualification Timelines.

3.4.2. Dependence on Physician and Hospital Pharmacist Referral Relationships, Which Take Time to Establish and Sit Outside Any Single Compounding Pharmacy's Direct Control.

3.4.3. Raw Material Cost Dynamics for Active Pharmaceutical Ingredients and Excipients, Which Bear Directly on Compounding Cost and Pricing.

3.4.4. Competition Between National Specialists and Regional Compounding Pharmacies, Fragmenting Therapeutic Specialization and Geographic Coverage.

3.4.5. Long Qualification Periods Before a Hospital Pharmacy Department Approves a New Compounding Pharmacy for a Tender or Framework Agreement.

3.5. Opportunities

3.5.1. Underserved Therapeutic Categories Identified in the Report Competitive Mapping.

3.5.2. Considerable Untapped Regional Opportunity Relative to the Concentration of Established Compounding Pharmacies in Northern Italy.

3.5.3. Rare Disease Opportunities Identified in the Report Competitive Mapping, Where Commercial Dose Forms Remain Unavailable.

3.5.4. Veterinary Compounding Gaps Identified in the Report Competitive Mapping.

3.5.5. Personalized Nutraceutical Opportunities Identified in the Report Competitive Mapping.

3.5.6. Specialty Hormone Therapy Opportunities Identified in the Report Competitive Mapping.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Preparation Type

4.1. Magistral Preparations

4.2. Officinal Preparations

4.3. Sterile Compounded Preparations

4.4. Non-Sterile Compounded Preparations

4.5. Personalized Nutraceutical Formulations

4.6. Veterinary Galenic Preparations

5. Dosage Form

5.1. Capsules

5.2. Powders

5.3. Oral Liquids

5.4. Syrups

5.5. Suspensions

5.6. Creams

5.7. Ointments

5.8. Gels

5.9. Lotions

5.10. Suppositories

5.11. Vaginal Preparations

5.12. Ophthalmic Preparations

5.13. Injectable Preparations

5.14. Nasal Formulations

5.15. Transdermal Preparations

6. Therapeutic Application

6.1. Dermatology

6.2. Hormone Replacement Therapy

6.3. Pain Management

6.4. Pediatrics

6.5. Geriatrics

6.6. Rare Diseases

6.7. Oncology Supportive Care

6.8. Endocrinology

6.9. Gastroenterology

6.10. Neurology

6.11. Women's Health

6.12. Men's Health

6.13. Veterinary Medicine

7. Patient Category

7.1. Adult Patients

7.2. Pediatric Patients

7.3. Geriatric Patients

7.4. Chronic Disease Patients

7.5. Special Needs Patients

7.6. Rare Disease Patients

8. Prescription Model

8.1. Physician-Prescribed Magistral Preparations

8.2. Specialist-Initiated Preparations

8.3. Hospital-Originated Prescriptions

8.4. Veterinary Prescriptions

9. Pharmacy Type

9.1. Independent Galenic Pharmacies

9.2. Specialized Compounding Pharmacies

9.3. Hospital Pharmacies

9.4. Integrated Pharmacy Chains with Compounding Capability

10. Manufacturing Complexity

10.1. Simple Compounding

10.2. Medium Complexity Formulations

10.3. Advanced Personalized Formulations

10.4. Sterile High-Control Preparations

11. Regulatory Classification

11.1. AIFA-Compliant Preparations

11.2. European Pharmacopoeia-Based Preparations

11.3. Controlled Substance Preparations

11.4. Specialized Therapeutic Preparations

12. Business Model

12.1. Direct Patient Service

12.2. Physician Referral Model

12.3. Hospital Partnership Model

12.4. B2B Pharmacy Supply Model

13. Buyer Intelligence and Demand Landscape

13.1. Buyer Segmentation

13.1.1. Independent Physicians

13.1.2. Specialist Clinics

13.1.3. Hospitals

13.1.4. Healthcare Networks

13.1.5. Veterinary Clinics

13.1.6. Functional Medicine Providers

13.2. Buyer Industries

13.2.1. Healthcare

13.2.2. Clinical Care

13.2.3. Veterinary Healthcare

13.2.4. Personalized Medicine Services

13.2.5. Specialty Treatment Centers

13.3. Buyer Company Types

13.3.1. Hospitals

13.3.2. Private Clinics

13.3.3. Medical Centers

13.3.4. Physician Networks

13.3.5. Veterinary Groups

13.4. Country-Wise Buyer Mapping

13.4.1. Northern Italy

13.4.2. Central Italy

13.4.3. Southern Italy

13.4.4. Sicily and Islands

13.5. Regional Demand Clusters

13.5.1. Lombardy Healthcare Cluster

13.5.2. Veneto Healthcare Cluster

13.5.3. Emilia-Romagna Medical Innovation Corridor

13.5.4. Rome Healthcare Network

13.6. Buyer Scale Classification

13.6.1. Small Clinics

13.6.2. Mid-Sized Healthcare Groups

13.6.3. Large Hospital Systems

13.6.4. Academic Medical Centers

13.7. Procurement Models

13.7.1. Prescription-Based Procurement

13.7.2. Framework Supply Agreements

13.7.3. Hospital Tender Procurement

13.7.4. Long-Term Clinical Partnerships

13.8. Buying Triggers

13.8.1. Patient-Specific Needs

13.8.2. Commercial Product Shortages

13.8.3. Dosage Customization Requirements

13.8.4. Allergy-Free Formulation Needs

13.8.5. Compliance Improvement Goals

13.9. Decision-Maker Roles

13.9.1. Physicians

13.9.2. Hospital Pharmacists

13.9.3. Clinical Directors

13.9.4. Procurement Managers

13.9.5. Medical Directors

13.10. Budget Ownership

13.10.1. Hospital Pharmacy Departments

13.10.2. Clinical Departments

13.10.3. Private Clinics

13.10.4. Healthcare Groups

13.11. Vendor Selection Criteria

13.11.1. Regulatory Compliance

13.11.2. Quality Assurance

13.11.3. Formulation Expertise

13.11.4. Delivery Reliability

13.11.5. Therapeutic Specialization

13.12. Contract Value Bands

13.12.1. Small Prescription Volumes

13.12.2. Medium Clinical Supply Contracts

13.12.3. Large Institutional Supply Agreements

13.13. Sales Cycle Length

13.13.1. Immediate Prescription Fulfillment

13.13.2. 1 to 3 Month Clinical Qualification

13.13.3. 3 to 12 Month Institutional Procurement

13.14. Strategic Relevance for Sella Farmaceutici

13.14.1. Strategic Relevance for Sella Farmaceutici

14. Italy Market Analysis and Forecast (2026–2030)

14.1. Introduction

14.2. Market Share Analysis

14.3. Market Size and Forecast

14.4. Market Size and Forecast, By Geography

14.4.1. Veneto

14.4.1.1. Market Share Analysis

14.4.1.2. Market Size and Forecast

14.4.1.3. By Product

14.4.1.4. By Technology

14.4.1.5. By Application

14.4.1.6. By Customer

14.4.1.7. Padua

14.4.1.7.1. Market Share Analysis

14.4.1.7.2. Market Size and Forecast

14.4.1.7.3. By Product

14.4.1.7.4. By Technology

14.4.1.7.5. By Application

14.4.1.7.6. By Customer

14.4.1.8. Venice

14.4.1.8.1. Market Share Analysis

14.4.1.8.2. Market Size and Forecast

14.4.1.8.3. By Product

14.4.1.8.4. By Technology

14.4.1.8.5. By Application

14.4.1.8.6. By Customer

14.4.1.9. Verona

14.4.1.9.1. Market Share Analysis

14.4.1.9.2. Market Size and Forecast

14.4.1.9.3. By Product

14.4.1.9.4. By Technology

14.4.1.9.5. By Application

14.4.1.9.6. By Customer

14.4.2. Lombardy

14.4.2.1. Market Share Analysis

14.4.2.2. Market Size and Forecast

14.4.2.3. By Product

14.4.2.4. By Technology

14.4.2.5. By Application

14.4.2.6. By Customer

14.4.2.7. Milan

14.4.2.7.1. Market Share Analysis

14.4.2.7.2. Market Size and Forecast

14.4.2.7.3. By Product

14.4.2.7.4. By Technology

14.4.2.7.5. By Application

14.4.2.7.6. By Customer

14.4.2.8. Brescia

14.4.2.8.1. Market Share Analysis

14.4.2.8.2. Market Size and Forecast

14.4.2.8.3. By Product

14.4.2.8.4. By Technology

14.4.2.8.5. By Application

14.4.2.8.6. By Customer

14.4.2.9. Bergamo

14.4.2.9.1. Market Share Analysis

14.4.2.9.2. Market Size and Forecast

14.4.2.9.3. By Product

14.4.2.9.4. By Technology

14.4.2.9.5. By Application

14.4.2.9.6. By Customer

14.4.3. Emilia-Romagna

14.4.3.1. Market Share Analysis

14.4.3.2. Market Size and Forecast

14.4.3.3. By Product

14.4.3.4. By Technology

14.4.3.5. By Application

14.4.3.6. By Customer

14.4.3.7. Bologna

14.4.3.7.1. Market Share Analysis

14.4.3.7.2. Market Size and Forecast

14.4.3.7.3. By Product

14.4.3.7.4. By Technology

14.4.3.7.5. By Application

14.4.3.7.6. By Customer

14.4.3.8. Parma

14.4.3.8.1. Market Share Analysis

14.4.3.8.2. Market Size and Forecast

14.4.3.8.3. By Product

14.4.3.8.4. By Technology

14.4.3.8.5. By Application

14.4.3.8.6. By Customer

14.4.3.9. Modena

14.4.3.9.1. Market Share Analysis

14.4.3.9.2. Market Size and Forecast

14.4.3.9.3. By Product

14.4.3.9.4. By Technology

14.4.3.9.5. By Application

14.4.3.9.6. By Customer

14.4.4. Lazio

14.4.4.1. Market Share Analysis

14.4.4.2. Market Size and Forecast

14.4.4.3. By Product

14.4.4.4. By Technology

14.4.4.5. By Application

14.4.4.6. By Customer

14.4.4.7. Rome

14.4.4.7.1. Market Share Analysis

14.4.4.7.2. Market Size and Forecast

14.4.4.7.3. By Product

14.4.4.7.4. By Technology

14.4.4.7.5. By Application

14.4.4.7.6. By Customer

14.4.5. Piedmont

14.4.5.1. Market Share Analysis

14.4.5.2. Market Size and Forecast

14.4.5.3. By Product

14.4.5.4. By Technology

14.4.5.5. By Application

14.4.5.6. By Customer

14.4.5.7. Turin

14.4.5.7.1. Market Share Analysis

14.4.5.7.2. Market Size and Forecast

14.4.5.7.3. By Product

14.4.5.7.4. By Technology

14.4.5.7.5. By Application

14.4.5.7.6. By Customer

14.4.6. Tuscany

14.4.6.1. Market Share Analysis

14.4.6.2. Market Size and Forecast

14.4.6.3. By Product

14.4.6.4. By Technology

14.4.6.5. By Application

14.4.6.6. By Customer

14.4.6.7. Florence

14.4.6.7.1. Market Share Analysis

14.4.6.7.2. Market Size and Forecast

14.4.6.7.3. By Product

14.4.6.7.4. By Technology

14.4.6.7.5. By Application

14.4.6.7.6. By Customer

14.4.7. Campania

14.4.7.1. Market Share Analysis

14.4.7.2. Market Size and Forecast

14.4.7.3. By Product

14.4.7.4. By Technology

14.4.7.5. By Application

14.4.7.6. By Customer

14.4.7.7. Naples

14.4.7.7.1. Market Share Analysis

14.4.7.7.2. Market Size and Forecast

14.4.7.7.3. By Product

14.4.7.7.4. By Technology

14.4.7.7.5. By Application

14.4.7.7.6. By Customer

14.4.8. Sicily

14.4.8.1. Market Share Analysis

14.4.8.2. Market Size and Forecast

14.4.8.3. By Product

14.4.8.4. By Technology

14.4.8.5. By Application

14.4.8.6. By Customer

14.4.8.7. Palermo

14.4.8.7.1. Market Share Analysis

14.4.8.7.2. Market Size and Forecast

14.4.8.7.3. By Product

14.4.8.7.4. By Technology

14.4.8.7.5. By Application

14.4.8.7.6. By Customer

14.4.8.8. Catania

14.4.8.8.1. Market Share Analysis

14.4.8.8.2. Market Size and Forecast

14.4.8.8.3. By Product

14.4.8.8.4. By Technology

14.4.8.8.5. By Application

14.4.8.8.6. By Customer

15. Competition Analysis

15.1. Market Positioning Overview

15.1.1. National Specialists and Regional Compounding Pharmacies

15.1.2. Premium and Standard Personalized Formulation Providers

15.1.3. Therapeutic Specialization Comparison

15.1.4. Service-Level Differentiation

15.2. Competitive Benchmarking Metrics

15.2.1. Estimated Market Presence

15.2.2. Product Breadth

15.2.3. Therapeutic Coverage

15.2.4. Geographic Reach

15.2.5. Laboratory Capabilities

15.2.6. Sterile Preparation Capability

15.2.7. Regulatory Compliance Systems

15.2.8. Innovation Investments

15.3. Strategic Moves

15.3.1. Laboratory Expansions

15.3.2. New Therapeutic Formulations

15.3.3. Healthcare Partnerships

15.3.4. Technology Investments

15.3.5. Quality Certification Upgrades

15.3.6. Distribution Network Enhancements

15.4. Competitive Mapping & Gaps

15.4.1. Underserved Therapeutic Categories

15.4.2. Considerable Untapped Regional Opportunity

15.4.3. Rare Disease Opportunities

15.4.4. Veterinary Compounding Gaps

15.4.5. Personalized Nutraceutical Opportunities

15.4.6. Specialty Hormone Therapy Opportunities

16. Company Profiles

16.1. Sella Farmaceutici

16.1.1. Company Overview

16.1.2. Headquarters, Ownership and Founding Year

16.1.3. Workforce Estimate

16.1.4. Geographic Footprint

16.1.5. Personalized Galenic Portfolio

16.1.6. Therapeutic Focus Areas

16.1.7. Customer Segments Served

16.1.8. Distribution and GTM Model

16.1.9. Financial Indicators

16.1.10. Regulatory Certifications

16.1.11. Quality Systems

16.1.12. Strategic Partnerships

16.1.13. R&D and Formulation Innovation

16.1.14. Recent Developments

16.1.15. SWOT Snapshot

16.2. Farmacia Sant'Antonio

16.2.1. Company Overview

16.2.2. Headquarters, Ownership and Founding Year

16.2.3. Workforce Estimate

16.2.4. Geographic Footprint

16.2.5. Personalized Galenic Portfolio

16.2.6. Therapeutic Focus Areas

16.2.7. Customer Segments Served

16.2.8. Distribution and GTM Model

16.2.9. Financial Indicators

16.2.10. Regulatory Certifications

16.2.11. Quality Systems

16.2.12. Strategic Partnerships

16.2.13. R&D and Formulation Innovation

16.2.14. Recent Developments

16.2.15. SWOT Snapshot

16.3. Farmacia Legnani

16.3.1. Company Overview

16.3.2. Headquarters, Ownership and Founding Year

16.3.3. Workforce Estimate

16.3.4. Geographic Footprint

16.3.5. Personalized Galenic Portfolio

16.3.6. Therapeutic Focus Areas

16.3.7. Customer Segments Served

16.3.8. Distribution and GTM Model

16.3.9. Financial Indicators

16.3.10. Regulatory Certifications

16.3.11. Quality Systems

16.3.12. Strategic Partnerships

16.3.13. R&D and Formulation Innovation

16.3.14. Recent Developments

16.3.15. SWOT Snapshot

16.4. Farmacia Serra

16.4.1. Company Overview

16.4.2. Headquarters, Ownership and Founding Year

16.4.3. Workforce Estimate

16.4.4. Geographic Footprint

16.4.5. Personalized Galenic Portfolio

16.4.6. Therapeutic Focus Areas

16.4.7. Customer Segments Served

16.4.8. Distribution and GTM Model

16.4.9. Financial Indicators

16.4.10. Regulatory Certifications

16.4.11. Quality Systems

16.4.12. Strategic Partnerships

16.4.13. R&D and Formulation Innovation

16.4.14. Recent Developments

16.4.15. SWOT Snapshot

16.5. Farmacia Internazionale

16.5.1. Company Overview

16.5.2. Headquarters, Ownership and Founding Year

16.5.3. Workforce Estimate

16.5.4. Geographic Footprint

16.5.5. Personalized Galenic Portfolio

16.5.6. Therapeutic Focus Areas

16.5.7. Customer Segments Served

16.5.8. Distribution and GTM Model

16.5.9. Financial Indicators

16.5.10. Regulatory Certifications

16.5.11. Quality Systems

16.5.12. Strategic Partnerships

16.5.13. R&D and Formulation Innovation

16.5.14. Recent Developments

16.5.15. SWOT Snapshot

16.6. Farmacia Del Naviglio

16.6.1. Company Overview

16.6.2. Headquarters, Ownership and Founding Year

16.6.3. Workforce Estimate

16.6.4. Geographic Footprint

16.6.5. Personalized Galenic Portfolio

16.6.6. Therapeutic Focus Areas

16.6.7. Customer Segments Served

16.6.8. Distribution and GTM Model

16.6.9. Financial Indicators

16.6.10. Regulatory Certifications

16.6.11. Quality Systems

16.6.12. Strategic Partnerships

16.6.13. R&D and Formulation Innovation

16.6.14. Recent Developments

16.6.15. SWOT Snapshot

16.7. Farmacia San Carlo

16.7.1. Company Overview

16.7.2. Headquarters, Ownership and Founding Year

16.7.3. Workforce Estimate

16.7.4. Geographic Footprint

16.7.5. Personalized Galenic Portfolio

16.7.6. Therapeutic Focus Areas

16.7.7. Customer Segments Served

16.7.8. Distribution and GTM Model

16.7.9. Financial Indicators

16.7.10. Regulatory Certifications

16.7.11. Quality Systems

16.7.12. Strategic Partnerships

16.7.13. R&D and Formulation Innovation

16.7.14. Recent Developments

16.7.15. SWOT Snapshot

16.8. Farmacia Vigorito

16.8.1. Company Overview

16.8.2. Headquarters, Ownership and Founding Year

16.8.3. Workforce Estimate

16.8.4. Geographic Footprint

16.8.5. Personalized Galenic Portfolio

16.8.6. Therapeutic Focus Areas

16.8.7. Customer Segments Served

16.8.8. Distribution and GTM Model

16.8.9. Financial Indicators

16.8.10. Regulatory Certifications

16.8.11. Quality Systems

16.8.12. Strategic Partnerships

16.8.13. R&D and Formulation Innovation

16.8.14. Recent Developments

16.8.15. SWOT Snapshot

16.9. Farmacia San Giuseppe

16.9.1. Company Overview

16.9.2. Headquarters, Ownership and Founding Year

16.9.3. Workforce Estimate

16.9.4. Geographic Footprint

16.9.5. Personalized Galenic Portfolio

16.9.6. Therapeutic Focus Areas

16.9.7. Customer Segments Served

16.9.8. Distribution and GTM Model

16.9.9. Financial Indicators

16.9.10. Regulatory Certifications

16.9.11. Quality Systems

16.9.12. Strategic Partnerships

16.9.13. R&D and Formulation Innovation

16.9.14. Recent Developments

16.9.15. SWOT Snapshot

16.10. Farmacia Mazzini

16.10.1. Company Overview

16.10.2. Headquarters, Ownership and Founding Year

16.10.3. Workforce Estimate

16.10.4. Geographic Footprint

16.10.5. Personalized Galenic Portfolio

16.10.6. Therapeutic Focus Areas

16.10.7. Customer Segments Served

16.10.8. Distribution and GTM Model

16.10.9. Financial Indicators

16.10.10. Regulatory Certifications

16.10.11. Quality Systems

16.10.12. Strategic Partnerships

16.10.13. R&D and Formulation Innovation

16.10.14. Recent Developments

16.10.15. SWOT Snapshot

16.11. Farmacia Loreto

16.11.1. Company Overview

16.11.2. Headquarters, Ownership and Founding Year

16.11.3. Workforce Estimate

16.11.4. Geographic Footprint

16.11.5. Personalized Galenic Portfolio

16.11.6. Therapeutic Focus Areas

16.11.7. Customer Segments Served

16.11.8. Distribution and GTM Model

16.11.9. Financial Indicators

16.11.10. Regulatory Certifications

16.11.11. Quality Systems

16.11.12. Strategic Partnerships

16.11.13. R&D and Formulation Innovation

16.11.14. Recent Developments

16.11.15. SWOT Snapshot

16.12. Farmacia Al Vigentino

16.12.1. Company Overview

16.12.2. Headquarters, Ownership and Founding Year

16.12.3. Workforce Estimate

16.12.4. Geographic Footprint

16.12.5. Personalized Galenic Portfolio

16.12.6. Therapeutic Focus Areas

16.12.7. Customer Segments Served

16.12.8. Distribution and GTM Model

16.12.9. Financial Indicators

16.12.10. Regulatory Certifications

16.12.11. Quality Systems

16.12.12. Strategic Partnerships

16.12.13. R&D and Formulation Innovation

16.12.14. Recent Developments

16.12.15. SWOT Snapshot

16.13. Farmacia del Corso

16.13.1. Company Overview

16.13.2. Headquarters, Ownership and Founding Year

16.13.3. Workforce Estimate

16.13.4. Geographic Footprint

16.13.5. Personalized Galenic Portfolio

16.13.6. Therapeutic Focus Areas

16.13.7. Customer Segments Served

16.13.8. Distribution and GTM Model

16.13.9. Financial Indicators

16.13.10. Regulatory Certifications

16.13.11. Quality Systems

16.13.12. Strategic Partnerships

16.13.13. R&D and Formulation Innovation

16.13.14. Recent Developments

16.13.15. SWOT Snapshot

16.14. Farmacia Centrale Firenze

16.14.1. Company Overview

16.14.2. Headquarters, Ownership and Founding Year

16.14.3. Workforce Estimate

16.14.4. Geographic Footprint

16.14.5. Personalized Galenic Portfolio

16.14.6. Therapeutic Focus Areas

16.14.7. Customer Segments Served

16.14.8. Distribution and GTM Model

16.14.9. Financial Indicators

16.14.10. Regulatory Certifications

16.14.11. Quality Systems

16.14.12. Strategic Partnerships

16.14.13. R&D and Formulation Innovation

16.14.14. Recent Developments

16.14.15. SWOT Snapshot

16.15. Farmacia Comunale Torino

16.15.1. Company Overview

16.15.2. Headquarters, Ownership and Founding Year

16.15.3. Workforce Estimate

16.15.4. Geographic Footprint

16.15.5. Personalized Galenic Portfolio

16.15.6. Therapeutic Focus Areas

16.15.7. Customer Segments Served

16.15.8. Distribution and GTM Model

16.15.9. Financial Indicators

16.15.10. Regulatory Certifications

16.15.11. Quality Systems

16.15.12. Strategic Partnerships

16.15.13. R&D and Formulation Innovation

16.15.14. Recent Developments

16.15.15. SWOT Snapshot

16.16. Farmacia del Leone

16.16.1. Company Overview

16.16.2. Headquarters, Ownership and Founding Year

16.16.3. Workforce Estimate

16.16.4. Geographic Footprint

16.16.5. Personalized Galenic Portfolio

16.16.6. Therapeutic Focus Areas

16.16.7. Customer Segments Served

16.16.8. Distribution and GTM Model

16.16.9. Financial Indicators

16.16.10. Regulatory Certifications

16.16.11. Quality Systems

16.16.12. Strategic Partnerships

16.16.13. R&D and Formulation Innovation

16.16.14. Recent Developments

16.16.15. SWOT Snapshot

16.17. Farmacia Federici

16.17.1. Company Overview

16.17.2. Headquarters, Ownership and Founding Year

16.17.3. Workforce Estimate

16.17.4. Geographic Footprint

16.17.5. Personalized Galenic Portfolio

16.17.6. Therapeutic Focus Areas

16.17.7. Customer Segments Served

16.17.8. Distribution and GTM Model

16.17.9. Financial Indicators

16.17.10. Regulatory Certifications

16.17.11. Quality Systems

16.17.12. Strategic Partnerships

16.17.13. R&D and Formulation Innovation

16.17.14. Recent Developments

16.17.15. SWOT Snapshot

16.18. Farmacia Cavour

16.18.1. Company Overview

16.18.2. Headquarters, Ownership and Founding Year

16.18.3. Workforce Estimate

16.18.4. Geographic Footprint

16.18.5. Personalized Galenic Portfolio

16.18.6. Therapeutic Focus Areas

16.18.7. Customer Segments Served

16.18.8. Distribution and GTM Model

16.18.9. Financial Indicators

16.18.10. Regulatory Certifications

16.18.11. Quality Systems

16.18.12. Strategic Partnerships

16.18.13. R&D and Formulation Innovation

16.18.14. Recent Developments

16.18.15. SWOT Snapshot

Frequently Asked Questions

Galenici Personalizzati, personalized compounding pharmaceuticals, covers magistral and officinal preparations compounded in pharmacy for individual patients. The Italy market is estimated at approximately USD 380 Million in 2025 and is projected to reach approximately USD 495 Million by 2030, expanding at a compound annual growth rate of roughly 5.4 percent.

A medicine compounded in a pharmacy on the basis of an individual physician's prescription for a specific patient. This report describes the category strictly as a market segment.

Lombardy accounts for the largest regional concentration, covered through Milan, Brescia and Bergamo, anchored by the Lombardy Healthcare Cluster and a dense concentration of hospital and specialist referral relationships.

Rising patient-specific dosage customization needs are the leading driver, including allergy-free and non-standard-strength formulations that route physician referrals toward compounding pharmacies.

A magistral preparation is compounded on the basis of an individual physician's prescription for a specific patient, while an officinal preparation is compounded to a recognised pharmacopoeia formula rather than an individual prescription.

Independent physicians, specialist clinics and hospitals most commonly prescribe these preparations, working within physician-prescribed magistral, specialist-initiated, hospital-originated or veterinary prescription models.

Pain management generates particularly consistent demand, alongside steady demand from dermatology, hormone replacement therapy and pediatrics.

AIFA-compliant preparations are one of four regulatory classification categories this report tracks, reflecting a preparation's alignment with Agenzia Italiana del Farmaco requirements as a market-access category rather than a description of any clinical outcome.

Fifteen dosage forms are tracked, from capsules, powders and oral liquids through creams, gels and suppositories to injectable and transdermal preparations, each paired with a specific administration route.

Inquire Before Buying Request Free Sample Ask For Discount

Italy compounding pharmacy scope matched directly to this report's personalized compounding boundary

Independent market research trackers publish an Italy compounding pharmacies market category that covers magistral and officinal preparations compounded in pharmacy on an individual prescription basis, the same personalized compounding scope this report tracks. This is an unusually direct scope match rather than a category this report had to narrow down from a broader pharmaceutical aggregate.

Two independent published estimates triangulated to a common 2025 base year

One independent tracker reports the Italy compounding pharmacies market at approximately USD 326.7 Million in 2023 growing to approximately USD 459.8 Million by 2030 at roughly 5 percent CAGR; a second reports approximately USD 379.2 Million in 2024 growing to approximately USD 598.0 Million by 2032 at approximately 5.45 percent CAGR. Extrapolating both to a common 2025 base year produces a range of approximately USD 360 to 400 Million, and USD 380 Million was adopted near the midpoint.

Cross-checked against the broader Europe compounding pharmacy market

The broader Europe compounding pharmacies market is independently estimated at approximately USD 4.4 to 4.7 Billion across 2025 and 2026, growing at approximately 5.4 percent CAGR through 2034. Italy's adopted 5.4 percent CAGR sits directly in line with this pan-European growth pace, supporting the forecast trajectory adopted here.

Forecast basis and its principal sensitivity

The forecast to 2030 assumes Italian physician referral activity, hospital tender procurement and AIFA regulatory posture continue broadly on recent trends. Hospital tender procurement pace and any material shift in AIFA regulatory policy are the principal sensitivities, since compounding pharmacy demand tracks referral and compliance conditions more closely than any single preparation-type trend.

Frequently Asked Questions

Galenici Personalizzati, personalized compounding pharmaceuticals, covers magistral and officinal preparations compounded in pharmacy for individual patients. The Italy market is estimated at approximately USD 380 Million in 2025 and is projected to reach approximately USD 495 Million by 2030, expanding at a compound annual growth rate of roughly 5.4 percent.

A medicine compounded in a pharmacy on the basis of an individual physician's prescription for a specific patient. This report describes the category strictly as a market segment.

Lombardy accounts for the largest regional concentration, covered through Milan, Brescia and Bergamo, anchored by the Lombardy Healthcare Cluster and a dense concentration of hospital and specialist referral relationships.

Rising patient-specific dosage customization needs are the leading driver, including allergy-free and non-standard-strength formulations that route physician referrals toward compounding pharmacies.

A magistral preparation is compounded on the basis of an individual physician's prescription for a specific patient, while an officinal preparation is compounded to a recognised pharmacopoeia formula rather than an individual prescription.

Independent physicians, specialist clinics and hospitals most commonly prescribe these preparations, working within physician-prescribed magistral, specialist-initiated, hospital-originated or veterinary prescription models.

Pain management generates particularly consistent demand, alongside steady demand from dermatology, hormone replacement therapy and pediatrics.

AIFA-compliant preparations are one of four regulatory classification categories this report tracks, reflecting a preparation's alignment with Agenzia Italiana del Farmaco requirements as a market-access category rather than a description of any clinical outcome.

Fifteen dosage forms are tracked, from capsules, powders and oral liquids through creams, gels and suppositories to injectable and transdermal preparations, each paired with a specific administration route.

Inquire Before Buying Request Free Sample Ask For Discount